瑞舒伐他汀联合普罗布考对冠心病合并高胆固醇血症患者血脂代谢及血管内皮功能的影响  

Impact of Rosuvastatin Combined with Probucol on Blood Lipids Metabolism and Vascular Endothelial Function in Coronary Heart Disease Patients Complicated with Hypercholesterolemia

作　　者：黄海涛 刘宏军[1] 陈茂华[1] 叶攀[1] 

机构地区：[1]三峡大学中医临床医学院.宜昌市中医医院,湖北省宜昌市443000

出　　处：《实用心脑肺血管病杂志》2017年第12期34-37,共4页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：目的探讨瑞舒伐他汀联合普罗布考对冠心病(CHD)合并高胆固醇血症患者血脂代谢及血管内皮功能的影响。方法选取2016年3月—2017年3月宜昌市中医医院收治的CHD合并高胆固醇血症患者98例,采用随机数字表法分为对照组和研究组,每组49例。在常规治疗基础上,对照组患者给予瑞舒伐他汀治疗,研究组患者给予瑞舒伐他汀联合普罗布考治疗;两组患者均连续治疗3个月。比较两组患者治疗前后血脂指标、脂代谢指标及血管内皮功能指标,并观察两组患者治疗期间不良反应发生情况。结果治疗前两组患者血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平比较,差异无统计学意义(P>0.05);治疗后研究组患者血清TC、TG、LDL-C水平低于对照组,血清HDL-C水平高于对照组(P<0.05)。治疗前两组患者血清载脂蛋白A1(Apo A1)和载脂蛋白B(Apo B)水平比较,差异无统计学意义(P>0.05);治疗后研究组患者血清Apo A1水平高于对照组,血清Apo B水平低于对照组(P<0.05)。治疗前两组患者血清一氧化氮(NO)、内皮素1(ET-1)水平及血流介导内皮舒张功能(FMD)比较,差异无统计学意义(P>0.05);治疗后研究组患者血清NO水平高于对照组,血清ET-1水平低于对照组,FMD优于对照组(P<0.05)。治疗期间两组患者均未出现明显不良反应。结论瑞舒伐他汀联合普罗布考可有效改善CHD合并高胆固醇血症患者血脂代谢及血管内皮功能,且安全性较高。Objective To inveterate the impact of rosuvastatin combined with probucol on blood lipids metabolism and vascular endothelial function in coronary heart disease patients complicated with hypercholesterolemia. Methods A total of 98 coronary heart disease patients complicated with hypercholesterolemia were selected in the Traditional Chinese Medicine Hospital of Yichang from March 2016 to March 2017, and they were divided into control group and study group according to random number table,each of 49 cases. Based on conventional treatment,patients in control group received rosuvastatin,while patients in study group received rosuvastatin combined with probucol; both groups continuously treated for 3 months. Blood lipids index,index of blood lipids metabolism and vascular endothelial function before and after treatment were compared between the two groups,and incidence of adverse reactions was observed during the treatment. Results No statistically significant differences of TC,TG,LDL-C or HDL-C was found between the two groups before treatment（ P〉0.05）; after treatment,TC,TG and LDL-C in study group were statistically significantly lower than those in control group, while HDL-C in study group was statistically significantly higher than that in control group（ P〈0.05）. No statistically significant differences of serum level of Apo A1 or Apo B was found between the two groups（ P〉0.05）; after treatment, serum Apo A1 level in study group was statistically significantly higher than that in control group,while serum Apo B level in study group was statistically significantly lower than that in control group（ P〈0.05）. No statistically significant differences of serum level of NO or ET-1,or FMD was found between the two groups before treatment（ P〉0.05）; after treatment,serum NO level in study group was statistically significantly higher than that in control group,serum ET-1 level in study group was statistically significantly lower than that in control group,meanwhile FMD in study group was statis

关 键 词：冠心病 高脂血症 瑞舒伐他汀 普罗布考 治疗结果 

分 类 号：R541.4[医药卫生—心血管疾病] R589.2[医药卫生—内科学]